Goldman Sachs Group Inc Durect Corp Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.43 - $5.9 $145,206 - $1.99 Million	-337,689 Reduced 90.93%	33,701 $19,000
Q3 2022 Nov 10, 2022	SELL	$0.43 - $5.9 $145,206 - $1.99 Million	-337,689 Reduced 90.93%	33,701 $0
Q2 2022 May 14, 2024	BUY	$0.38 - $0.64 $141,128 - $237,689	371,390 New	371,390 $177,000
Q2 2022 Aug 15, 2022	BUY	$0.38 - $0.64 $68,637 - $115,600	180,625 Added 94.68%	371,390 $177,000
Q1 2022 May 16, 2022	SELL	$0.55 - $0.98 $18,602 - $33,146	-33,823 Reduced 15.06%	190,765 $128,000
Q4 2021 Feb 14, 2022	BUY	$0.9 - $1.31 $29,926 - $43,560	33,252 Added 17.38%	224,588 $221,000
Q3 2021 Nov 10, 2021	BUY	$1.21 - $1.61 $231,516 - $308,050	191,336 New	191,336 $245,000

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $178M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.